Genmab Receives MHLW Approval for Epkinly (epcoritamab) for Adults Patients with Large B-Cell Lymphoma
- The MHLW has approved Epkinly (T-cell engaging bispecific Ab) for adult patients with certain types of r/r LBCL incl. DLBCL, HGBCL, PMBCL, and follicular lymphoma grade 3B (FL3B) after ≥2 lines of systemic therapy. Epcoritamab is being co-developed by Genmab & AbbVie
- The approval was based on the P-I/II (EPCORE NHL-1 & 3) trials evaluating the safety and preliminary efficacy of Epkinly monotx. In the (EPCORE NHL-1 & 3) trials, the results showed ORR (63% & 56%) & CR rates of (39% & 44%), 82.8% & 100% experienced treatment-related side effects
- Epcoritamab, an IgG1-bispecific Ab that has been developed using Genmab's DuoBody technology. The therapy was approved in the US in May 2023
Ref: Businesswire| Image: Genmab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.